Prostaglandin E2 Receptors on Human Peripheral Blood Monocytes

The prostaglandin E2 (PGE2) receptor on human peripheral blood monocytes is characterized. The receptor binding at physiological temperature and pH was saturable, specific, and reversible. Scatchard analysis of binding data revealed a linear plot giving a Kd= 1.1 ± 10‐9mol/l and Bmax=4.1 fmol/107 cells, equal to 240 binding sites per cell. PGE2 increased intracellular cyclic adenosine 5′‐monophosphate by a maximal factor of 3. PGF2α and archidonic acid had no stimulatory effects on adenyl cyclase, in accordance with their low binding to the cells. The characterization of the PGE2 receptor on human monocytes creates a basis for the study of the clinical significance of changes in PGE2‐receptor binding in disease states involving PGE2‐monocyte interactions such as various immunological disorders and bone resorption.

[1]  H. Beck-Nielsen,et al.  Prostaglandin E2 receptor binding and action in human fat cells. , 1984, The Journal of clinical endocrinology and metabolism.

[2]  S. Johnsen,et al.  Differences in Binding Sites for Prostaglandin E2 on Mononuclear Leucocytes from Human Newborns and from Their Mothers , 1983, Scandinavian journal of immunology.

[3]  C. Trummel,et al.  Monocyte-mediated bone resorption involves release of nondialyzable substances in addition to prostaglandin. , 1983, Journal of the Reticuloendothelial Society.

[4]  M. Goldyne,et al.  Human monocytes synthesize eicosanoids from T lymphocyte-derived arachidonic acid. , 1982, Prostaglandins.

[5]  R. Fisher,et al.  Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide. , 1982, Journal of immunology.

[6]  K. Whaley,et al.  Prostaglandins and prostaglandin synthetase inhibitors regulate the synthesis of complement components by human monocytes. , 1982, Clinical and experimental immunology.

[7]  E. Krawitt,et al.  Studies on lymphocyte hyporesponsiveness in cirrhosis: the role of increased monocyte suppressor cell activity. , 1982, Gastroenterology.

[8]  G. Mundy.  Role of monocytes in bone resorption. , 1982, Advances in experimental medicine and biology.

[9]  S. Anderson,et al.  Regulation of human natural killing. I. The role of monocytes, interferon, and prostaglandins. , 1981, Journal of immunology.

[10]  K. Kragballe,et al.  Transient cyclic AMP accumulation during antibody-dependent cytotoxicity mediated by monocytes and neutrophils. , 1981, Immunology.

[11]  M. A. Bray,et al.  Prostaglandin generation by separated human blood mononuclear cell fractions. , 1981, International journal of immunopharmacology.

[12]  M. Goldyne,et al.  Prostaglandin E2 as a modulator of macrophage-T lymphocyte interactions. , 1980, The Journal of investigative dermatology.

[13]  R. Williams,et al.  High-affinity binding sites for prostaglandin E on human lymphocytes. , 1979, Cellular immunology.

[14]  A. Gilman,et al.  Binding of (3H)prostaglandin E1 to putative receptors linked to adenylate cyclase of cultured cell clones. , 1976, The Journal of biological chemistry.

[15]  C. Rao.  Characterization of prostaglandin receptors in the bovine corpus luteum cell membranes. , 1974, The Journal of biological chemistry.

[16]  F. Charalampous,et al.  Energy Source for Active Transport of α-Aminoisobutyric Acid in KB Cells , 1974 .

[17]  G. Weissmann,et al.  Mechanisms of lysosomal enzyme release from human leukocytes. II. Effects of cAMP and cGMP, autonomic agonists, and agents which affect microtubule function. , 1974, The Journal of clinical investigation.

[18]  B. Schaumburg,et al.  Binding of prostaglandin E1 to rat thymocytes. , 1973, Biochimica et biophysica acta.

[19]  J. Wolff,et al.  Binding of prostaglandin E1 to beef thyroid membranes. , 1973, The Journal of biological chemistry.

[20]  G. Weissmann,et al.  MECHANISMS OF LYSOSOMAL ENZYME RELEASE FROM HUMAN LEUKOCYTES , 1973, The Journal of cell biology.